ClinicalTrials.gg
CompletedNCT05176314Updated Sep 19, 2024Results posted

A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LY3527727) and Rosuvastatin in Healthy Participants

A Phase 1 interventional study of Rosuvastatin and Pirtobrutinib in Healthy, sponsored by Loxo Oncology, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Loxo Oncology, Inc. (part of Eli Lilly and Company) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years to 64 Years
Sex
All
01

Study summary

The main purpose of this study is to determine the effect of pirtobrutinib on the levels of rosuvastatin in the blood stream in healthy participants. This study will also evaluate the safety and tolerability of rosuvastatin when administered in combination with pirtobrutinib in healthy participants. This study will last up to approximately 26 days excluding screening period.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Loxo Oncology, Inc. is the lead sponsor of 17 studies on the registry; 2 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.

First submitted after Loxo Oncology, Inc. became part of Eli Lilly and Company.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, and vital signs.
  • (BMI) within the range of 18.0 to 32.0 kilograms per meter squared (kg/m²) and a body weight of at least 50 kg.
  • Males, or female participants who are not of .

Exclusion criteria

Exclusion Criteria:

  • Have known allergies to pirtobrutinib or rosuvastatin, related compounds, or any components of the formulation.
  • Have an abnormal blood pressure and/or pulse rate, deemed to be by the investigator.
  • Have a significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, neurological, or psychiatric disorder or surgery (including cholecystectomy) capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the product; or of interfering with the interpretation of data.
  • Have used or intend to use prescription or nonprescription medication (including dietary supplements, vitamins, and/or herbal medications), or modulators of or BCRP within 7 days prior to dosing, unless, in the opinion of the investigator and sponsor, the medication will not interfere with the study.
  • Have c.34AA, c.421AA, or c.34GA/421CA genotypes of ABCG2 as determined through genotyping.
  • Have c.521TC and c/521CC genotypes of SLCO1B1 as determined by genotyping.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Rosuvastatin + Pirtobrutinib

    Participants received study intervention through oral administration as follows: * Day 1: 20 milligram (mg) rosuvastatin alone * Day 6: 20 mg rosuvastatin co-administered with 200 mg pirtobrutinib * Days 7 to 12: Once daily (QD) doses of 200 mg pirtobrutinib alone * Day 13: 20 mg rosuvastatin co-administered with 200 mg pirtobrutinib * Days 14 to 17: QD doses of 200 mg pirtobrutinib alone.

    Drug: Rosuvastatin · Drug: Pirtobrutinib

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Rosuvastatin

    PK: Cmax of Rosuvastatin

    Time frame: Day 1, Day 6 and Day 13: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120 hours (h) post-dose.

  2. PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of Rosuvastatin

    PK: AUC(0-inf) of Rosuvastatin

    Time frame: Day 1, Day 6 and Day 13: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120 hours (h) post-dose.

07

Results

Posted Sep 19, 2024

Participant flow

Participant flow — Overall Study
MilestoneRosuvastatin + Pirtobrutinib
Started32
Safety population day 1, day 6 and days 7-1232
Safety population day 13, days 14-1731
Completed28
Not completed4
Withdrew: Lost to follow-up2
Withdrew: Physician decision1
Withdrew: Adverse event1

Outcome measures

PrimaryPharmacokinetics (PK): Maximum Concentration (Cmax) of Rosuvastatin

PK: Cmax of Rosuvastatin

Time frame:
Day 1, Day 6 and Day 13: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120 hours (h) post-dose.
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Rosuvastatin
nanograms per milliliter (ng/mL)Rosuvastatin + Pirtobrutinib
Day 19.45 ± 56
Day 623.0 ± 51
Day 1323.0 ± 49
PrimaryPK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of Rosuvastatin

PK: AUC(0-inf) of Rosuvastatin

Time frame:
Day 1, Day 6 and Day 13: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120 hours (h) post-dose.
Reported as:
Geometric mean · nanograms*hours per milliliter(ng*h/mL)
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of Rosuvastatin
nanograms*hours per milliliter(ng*h/mL)Rosuvastatin + Pirtobrutinib
Day 188.2 ± 44
Day 6189 ± 41
Day 13207 ± 40

Adverse events

Collected over Baseline to end of follow-up (up to 24 days).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
20 mg Rosuvastatin (Day 1)0/32 (0%)0/32 (0%)3/32 (9.4%)
20 mg Rosuvastatin + 200 mg Pirtobrutinib (Day 6)0/32 (0%)0/32 (0%)1/32 (3.1%)
200 mg Pirtobrutinib QD (Days 7-12)0/32 (0%)0/32 (0%)3/32 (9.4%)
20 mg Rosuvastatin + 200 mg Pirtobrutinib (Day 13)0/31 (0%)0/31 (0%)0/31 (0%)
200 mg Pirtobrutinib QD (Days 14-17)0/31 (0%)0/31 (0%)1/31 (3.2%)
Most frequent other events
Most frequent other events
Event20 mg Rosuvastatin (Day 1)20 mg Rosuvastatin + 200 mg Pirtobrutinib (Day 6)200 mg Pirtobrutinib QD (Days 7-12)20 mg Rosuvastatin + 200 mg Pirtobrutinib (Day 13)200 mg Pirtobrutinib QD (Days 14-17)
HeadacheNervous system disorders3/320/321/320/310/31
PetechiaeSkin and subcutaneous tissue disorders0/321/323/320/311/31

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)Rosuvastatin + Pirtobrutinib
Mean44.6 ± 10.6
Sex: Female, Male
Sex: Female, Male(Participants)Rosuvastatin + Pirtobrutinib
Female5
Male27
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Rosuvastatin + Pirtobrutinib
Hispanic or Latino6
Not Hispanic or Latino26
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Rosuvastatin + Pirtobrutinib
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American15
White15
More than one race2
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Rosuvastatin + Pirtobrutinib
United States32
08

Study locations

2 sites
  • QPS Bio-Kinetic Clinical Applications
    Springfield, Missouri 65802, United States
  • Covance Dallas
    Dallas, Texas 75247, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2022 to primary completion in Apr 2022, 3 months.

Results were first posted in Sep 2024, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2022
First posted
Jan 4, 2022
StartActual
Jan 11, 2022
Primary completionActual
Apr 20, 2022
CompletionActual
Apr 20, 2022
Results first posted
Sep 19, 2024
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05176314
Responsible party
Sponsor
First posted
Jan 4, 2022
Start date
Jan 11, 2022
Primary completion
Apr 20, 2022
Completion
Apr 20, 2022
Results posted
Sep 19, 2024
Last update
Sep 19, 2024

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pirtobrutinib

Start the discussion